Drug Database
Back to search

Poland· PL-100512748

Desferal

A deferoxamine product containing deferoxamini mesilas, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC V03AC01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDesferalATCV03AC01REGISTER NO.PL-100512748PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about deferoxamini mesilasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Deferoxamine is registered in 16 of 19 countries.

Countries holding a registration under ATC V03AC01 (deferoxamine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search deferoxamine products by name

Deferoxamine · ATC V03AC01

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deferoxamine costs, country by country.

Normalised to the WHO defined daily dose (2.8 g), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Deferoxamine · price per daily dose (2.8 g)

USD · FX 28 Sept 2026

  • CH Switzerland$48.38
  • FR France$33.66
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Deferoxamini mesilas
Manufacturer
Delfarma Sp. z o.o.
Country
Poland (PL)
ATC code
V03AC01
ATC class
Deferoxamine
Defined daily dose
2.8 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991564384

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

49 interactions on record for deferoxamine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check deferoxamine against other medicinesHow interaction checks work

Deferoxamine · interactions on record

49 records

  • 9 severe
  • 5 moderate
  • 35 info

Most severe, free to view

  • CidofovirJ05AB12severe
  • VigabatrinN03AG04severe
  • InotersenN07XX15severe
  • IopamidolV08AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deferoxamine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deferoxamine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Desferal
  • Belgium · Desferal
  • Bulgaria · Десферал
  • Cyprus · Deferoxamine Noridem
  • Czechia · Desferal
  • Germany · Deferoxaminmesilat Noridem Enterprises, Desferal
  • Denmark · Desferal
  • Spain · Desferin
  • Finland · Desferal
  • France · Desferal
  • United Kingdom (Northern Ireland) · Desferrioxamine Mesilate Noridem Enterprises
  • Greece · Deferoxamine Noridem, Demoferidon
  • Hungary · Desferal
  • Ireland · Desferal
  • Iceland · Desferal
  • Italy · Deferoxamina Noridem, Desferal
  • Luxembourg · Desferal
  • Netherlands · Desferal
  • Norway · Desferal
  • Portugal · Desferal
  • Romania · Desferal
  • Sweden · Desferal

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cbd0f3d2-5500-4521-9e02-dd8a4c7d187e
GET /v1/drugs/cbd0f3d2-5500-4521-9e02-dd8a4c7d187e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05909991564384 ¦ Rp ¦ 160312\n10 fiol. 500 mg w proszku",
  "substance": "Deferoxamini mesilas 500 mg",
  "common_name": "Deferoxamini mesilas",
  "pl_product_id": "100512748",
  "pozwolenie_nr": "041/25",
  "auth_procedure": "IR",
  "authorisation_validity": "2030-01-29"
}
API referenceMCP serverPlans

See everything about deferoxamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console